Last reviewed 2026-05-24 · How we verify

VOCACAPSAICIN

Phase 2 active Small molecule ✓ Verified May 2026 Quality 15/100

VOCACAPSAICIN is a drug. It is currently in Phase 2 development.

Vocacapsaicin is a small molecule used to study the treatment of postsurgical pain and pain in clinical trials. It is being evaluated in a phase 1/2 study, CA-008, in comparison to placebo and ketorolac.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VOCACAPSAICIN
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

Constipation
Nausea
Headache
Pyrexia
Dizziness
Tachycardia
Vomiting
Pruritus
Pain in extremity
Hypoxia
Back pain
Peripheral swelling

Key clinical trials

Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin) (PHASE1, PHASE2)
Study in Subjects Undergoing Complete Abdominoplasty (PHASE2)
Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair (PHASE1, PHASE2)
Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty (PHASE2)
Open-Label CA-008 (Vocacapsaicin) in Bunionectomy (PHASE2)
Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VOCACAPSAICIN CI brief — competitive landscape report
VOCACAPSAICIN updates RSS · CI watch RSS

Frequently asked questions about VOCACAPSAICIN

What is VOCACAPSAICIN?

VOCACAPSAICIN is a Small molecule drug.

What development phase is VOCACAPSAICIN in?

VOCACAPSAICIN is in Phase 2.

What are the side effects of VOCACAPSAICIN?

Common side effects of VOCACAPSAICIN include Constipation, Nausea, Headache, Pyrexia, Dizziness, Tachycardia.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing